Remedium Lifecare announced strong financial results for the quarter and half-year.

Profit after tax for the quarter nearly doubled to 8.62 Cr, up 85.49% from the previous quarter, with EBITDA rising 82.70% to 10.44 Cr.

Half-year profit after tax reached 13.27 Cr, significantly higher than the previous full year.

The company’s consolidated revenue for the quarter was 111.06 Cr.

These results reflect operational discipline and business expansion.

Leadership was reinforced with new board appointments to focus on governance, global expansion, and scaling CDMO capabilities, strengthening its specialty pharma and chemicals business.